

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



	Section 1. Identify	ring Informa	ation						
	1. Given Name (First Name) Christopher		2. Surnan Denton	ne (Last Name)		3. Date 14-February-2019		
	4. Are you the corresponding a	author?	Yes	✓ No	Correspon Khanna	nding Autho	r's Name		
	5. Manuscript Title Disease awareness: risk fact lung	tors, biomark	ers, treatn	nent options	and unmet ne	eds of Sys	temic Sclerosis associated	d interstitial	
	6. Manuscript Identifying Num	nber (if you kno	ow it)						
	Section 2. The Wor	rk Under Co	nsiderat	tion for Puk	olication				
	Did you or your institution at a any aspect of the submitted we statistical analysis, etc.)?								
	Are there any relevant confl								
	If yes, please fill out the app Excess rows can be removed				nave more tha	n one entit	ty press the "ADD" buttor	ı to add a row.	
	Name of Institution/Comp	any	Grant?	Personal N	lon-Financial Support	Other?	Comments		
ln	ventiva		✓						
G	SK		✓						
C:	SL Behring		✓						
G	SK			✓					
C:	SL Behring			✓					
A	ctelion			✓					
Ba	ayer			\checkmark					
В	oehringer Ingelheim			\checkmark					
U	СВ			✓					
Sā	anofi			✓					
Ro	oche			✓					



Section 3. Relevant financial activities outside the submitted work.
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication . Are there any relevant conflicts of interest? Yes Vo
Section 4. Intellectual Property Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes V No
Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Denton reports grants from Inventiva, grants from GSK, grants from CSL Behring, personal fees from GSK, personal fees from CSL Behring, personal fees from Actelion, personal fees from Bayer, personal fees from Boehringer Ingelheim, personal fees from UCB, personal fees from Sanofi, personal fees from Roche, during the conduct of the study;



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

Desai 1



Section 1. Identifying Inform	nation	
1. Given Name (First Name) Sujal	2. Surname (Last Name) Desai	3. Date 16-August-2019
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Dinesh Khanna
5. Manuscript Title Aetiology, Risk Factors, and Biomarkers	s in Systemic Sclerosis with	Interstitial Lung Disease
6. Manuscript Identifying Number (if you k	now it)	
Section 2. The Work Under C	onsideration for Public	cation
	g but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for at a monitoring board, study design, manuscript preparation,
Section 3. Relevant financial	activities outside the s	submitted work.
of compensation) with entities as descr	ibed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
Section 4. Intellectual Prope	rty Patents & Copyric	ghts
Do you have any patents, whether plan	ned, pending or issued, br	roadly relevant to the work? Yes V No

Desai 2



Section 5. Relationships not covered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
✓ Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
Co-organiser of the Boehringer-Ingelheim ILD Multidisciplinary Masterclass in Interstitial Lung Diseases. I am paid an honorarium and travel expenses. The course does NOT promote any treatments/management startegies.
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Desai 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your



Section 1. Identifying Information	ation					
1. Given Name (First Name) Dinesh	2. Surna Khanna	me (Last Nar	me)		3. Date 12-February-2019	
4. Are you the corresponding author?	✓ Yes	No				
5. Manuscript Title Unmet Needs, Risk Factors and Biomarke	ers in Syst	temic Sclere	osis with Interstiti	al Lung D	Disease	
6. Manuscript Identifying Number (if you known) N/A	ow it)					
Section 2. The Work Under Co	nsidera	tion for P	ublication			
Did you or your institution at any time receivany aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of interesting the state of the submitted work in the state of the stat	but not lin st? ✓ rmation k	nited to gran	nts, data monitoring	board, st	udy design, manuscript preparation,	
Name of Institution/Company	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Actelion		V			consultancy as part of trial design	_
Astra Zeneca		✓			Outside of this study subject (Gout)	
Bayer	V	✓			Consultancy as part of trial design and lead Pl	
BMS	✓	✓			Consultancy as part of trial design and lead PI	
Boehringer-Ingelheim	✓	\checkmark			Consultancy as part of trial design	
Chemomab		✓			Consultancy as part of trial design	
ivi Biopharma		✓			Employee	
Corbus		✓			Consultancy as part of trial design	
CSL Behring		✓			Consultancy as part of trial design	
Cytori		✓			Consultancy as part of trial design	
iicos		\checkmark			Ownership interest	
MD Serono		✓			Consultancy as part of trial design	



Name of Institution/Company	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Genetech/Roche	V	✓			Consultancy as part of trial design and lead PI	
GSK		V			Consultancy as part of trial design and lead PI	
Horizon		✓			Consultancy as part of trial design	
NIH NIAID	✓				Grant; lead PI	
NIH NIAMS	✓				Grant; lead PI	
Pfizer	✓				Consultancy as part of trial design and lead Pl	
Sanofi-Aventis/Genzy	✓	✓			Consultancy as part of trial design and lead PI	
UCB Pharma		✓			Consultancy as part of trial design	
Place a check in the appropriate boxes in of compensation) with entities as describ clicking the "Add +" box. You should report there any relevant conflicts of interest If yes, please fill out the appropriate information.	the table bed in the ort relations:	e to indicate instruction onships tha	e whether you hans. Use one line fo	ive financ or each er	ntity; add as many lines as you need	
Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Astra Zeneca		✓			Gout	
Section 4. Intellectual Propert	y Pate	ents & Cop	pyrights			
Do you have any patents, whether plann	ed, pendi	ing or issue	ed, broadly releva	nt to the	work? Yes 🗸 No	



Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
	wing relationships/conditions/circumstances are present (explain below): tionships/conditions/circumstances that present a potential conflict of interest
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ve disclosures, this form will automatically generate a disclosure statement, which will appear in the box

below.

Dr. Khanna reports personal fees from Actelion, personal fees from Astra Zeneca, grants and personal fees from Bayer, grants and personal fees from BMS, grants and personal fees from Boehringer-Ingelheim, personal fees from Chemomab, personal fees from Civi Biopharma, personal fees from Corbus, personal fees from CSL Behring, personal fees from Cytori, personal fees from Eicos, personal fees from EMD Serono, grants and personal fees from Genetech/Roche, personal fees from GSK, personal fees from Horizon, grants from NIH NIAID, grants from NIH NIAMS, grants from Pfizer, grants and personal fees from Sanofi-Aventis/Genzy, personal fees from UCB Pharma, during the conduct of the study; personal fees from Astra Zeneca, outside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Renzoni 1



Section 1.	Identifying Inform	ation	
1. Given Name (Fi Elisabetta	rst Name)	2. Surname (Last Nam Renzoni	e) 3. Date 14-February-2019
4. Are you the cor	responding author?	☐ Yes ✓ No	Corresponding Author's Name Dinesh Khanna
5. Manuscript Title Disease awarene		ers and unmet needs	of systemic sclerosis associated interstitial lung disease
6. Manuscript Idei	ntifying Number (if you kn	ow it)	
	<u> </u>		
Section 2.	The Work Under Co	onsideration for Pu	blication
any aspect of the s statistical analysis,	ubmitted work (including	but not limited to grant	rom a third party (government, commercial, private foundation, etc.) for s, data monitoring board, study design, manuscript preparation, lo
Section 3.	Relevant financial	activities outside tl	he submitted work.
of compensation clicking the "Ado Are there any rel) with entities as descri	bed in the instructions port relationships that est?	whether you have financial relationships (regardless of amount s. Use one line for each entity; add as many lines as you need by were present during the 36 months prior to publication .
Name of Entity		Grant? Personal Fees?	Non-Financial Support? Comments
Boehringer-Ingelheir	n		Lecture and advisory board fees
Roche			Lecture and advisory board fees
Mundipharma			Lecture fees
Section 4.	Intellectual Proper	ty Patents & Cop	yrights
Do you have any			d, broadly relevant to the work? Yes V No

Renzoni 2



Section 5. Polationships not severed shows
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Renzoni reports lecture fees and advisory board fees from Boehringer-Ingelheim and Roche, and lecture fees from Mundipharma, outside the submitted work.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Renzoni 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

Tashkin 1



Section 1. Identifyin	g Information	
1. Given Name (First Name) Donald	2. Surname (Last Name) Tashkin	3. Date 13-February-2019
4. Are you the corresponding au	thor? Yes ✓ No	Corresponding Author's Name Dinesh Khanna
5. Manuscript Title Disease awareness: risk factor	s, biomarkers and unmet needs of s	systemic sclerosis associated interstitial lung disease
6. Manuscript Identifying Number	er (if you know it)	_
Section 2. The Work		
The Work	Under Consideration for Public	cation
	(including but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation,
Section 3. Relevant f	nancial activities outside the s	submitted work.
of compensation) with entities clicking the "Add +" box. You	s as described in the instructions. Us should report relationships that wer	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
Are there any relevant conflict		
If yes, please fill out the appro	priate information below.	
Name of Entity	Grant? Personal No	on-Financial Other? Comments
EMD Serano		Consultant
Boehringer-Ingelheim		Consultant
Genentech		Consultant
Section 4		
Section 4. Intellectua	l Property Patents & Copyri	ghts
Do you have any patents, whe	ther planned, pending or issued, br	roadly relevant to the work? Yes V No

Tashkin 2



Castian F	
Section 5.	Relationships not covered above
	relationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	owing relationships/conditions/circumstances are present (explain below):
✓ No other rel	ationships/conditions/circumstances that present a potential conflict of interest
	nanuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements urnals may ask authors to disclose further information about reported relationships.
Section 6.	
	Disclosure Statement
Based on the ab below.	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
	orts personal fees from EMD Serano, personal fees from Boehringer-Ingelheim, personal fees from tside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Tashkin 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Varga

5.



1. Given Name (First Name) John	2. Surname (Last Name) Varga	3. Date 14-February-2019
4. Are you the corresponding author?	Yes Vo	Corresponding Author's Name Dinesh Khanna
5. Manuscript Title Disease awareness: risk factors, bio	markers and unmet needs of s	systemic sclerosis associated interstitial lung disease
6. Manuscript Identifying Number (if yo	ou know it)	
Section 2		
THE RESERVE OF THE PARTY OF THE	er Consideration for Public	
Did you or your institution at any time	receive payment or services from	a third party (government, commercial, private foundation, etc.) f ata monitoring board, study design, manuscript preparation,
	daning backnot minited to granta, as	year morning Boar a, occasi, according to
statistical analysis, etc.)?	12-27	Act monitoring society acting the second property of the second prop
statistical analysis, etc.)?	12-27	
statistical analysis, etc.)?	12-27	
statistical analysis, etc.)? Are there any relevant conflicts of in	nterest? Yes V No	
Section 3. Relevant finan Place a check in the appropriate be	cial activities outside the sexes in the table to indicate whe secribed in the instructions. U	submitted work. nether you have financial relationships (regardless of amoun se one line for each entity; add as many lines as you need by
Section 3. Relevant finan Place a check in the appropriate boof compensation) with entities as delicking the "Add +" box. You should	cial activities outside the sexes in the table to indicate whe scribed in the instructions. Ud report relationships that we	submitted work. Tether you have financial relationships (regardless of amoun
statistical analysis, etc.)? Are there any relevant conflicts of in Section 3. Relevant finan Place a check in the appropriate be of compensation) with entities as definitions.	cial activities outside the exes in the table to indicate whe escribed in the instructions. U d report relationships that we interest?	submitted work. nether you have financial relationships (regardless of amoun se one line for each entity; add as many lines as you need by
Section 3. Relevant finan Place a check in the appropriate bo of compensation) with entities as d clicking the "Add +" box. You shoul Are there any relevant conflicts of i	cial activities outside the exes in the table to indicate whe escribed in the instructions. U d report relationships that we interest? Yes No e information below.	submitted work. mether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication. n-Financial Other? Comments
Section 3. Relevant finan Place a check in the appropriate boo of compensation) with entities as of clicking the "Add +" box. You should Are there any relevant conflicts of it if yes, please fill out the appropriate was a characteristic of the section of the s	cial activities outside the exes in the table to indicate whe escribed in the instructions. U d report relationships that we interest? Yes No e information below.	submitted work. The sether you have financial relationships (regardless of amoung se one line for each entity; add as many lines as you need by the present during the 36 months prior to publication.
Section 3. Relevant finan Place a check in the appropriate boot of compensation) with entities as of clicking the "Add +" box. You should Are there any relevant conflicts of it if yes, please fill out the appropriate where of Entity Name of Entity	cial activities outside the sexes in the table to indicate whe escribed in the instructions. Und report relationships that we interest? Yes No e information below. Grant? Personal No Fees?	submitted work. The sether you have financial relationships (regardless of amount see one line for each entity; add as many lines as you need by the present during the 36 months prior to publication. The set of the set
Section 3. Relevant finan Place a check in the appropriate book of compensation) with entities as of clicking the "Add +" box. You should have there any relevant conflicts of it if yes, please fill out the appropriate warms of Entity Name of Entity Characteristics and the section of the	cial activities outside the sexes in the table to indicate whe escribed in the instructions. Und report relationships that we interest? Yes No e information below. Grant? Personal No Fees?	submitted work. The sether you have financial relationships (regardless of amount see one line for each entity; add as many lines as you need by the present during the 36 months prior to publication. The seture and advisory board fees
Section 3. Relevant finan Place a check in the appropriate boot of compensation) with entities as of clicking the "Add +" box. You should have there any relevant conflicts of it lif yes, please fill out the appropriate warms of Entity	cial activities outside the sexes in the table to indicate whe escribed in the instructions. Und report relationships that we interest? Yes No e information below. Grant? Personal No Fees?	submitted work. The sether you have financial relationships (regardless of amount see one line for each entity; add as many lines as you need by the present during the 36 months prior to publication. The seture and advisory board fees
Section 3. Relevant finan Place a check in the appropriate book of compensation) with entities as of clicking the "Add +" box. You should Are there any relevant conflicts of it if yes, please fill out the appropriate warms of Entity Name of Entity The entity is a characteristic and the second conflicts of its properties.	cial activities outside the sexes in the table to indicate whe escribed in the instructions. Und report relationships that we interest? Yes No e information below. Grant? Personal No Fees?	submitted work. The sether you have financial relationships (regardless of amount see one line for each entity; add as many lines as you need by the present during the 36 months prior to publication. The seture and advisory board fees



Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Varga reports lecture fees and advisory board fees from Boehringer-Ingelheim and lecture fees from Corbus outside the submitted work.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.